Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.
Carsten BokemeyerNoman ParachaUlrik N LassenAntoine ItalianoSean D SullivanMarisca MarianNicoletta BregaJesús García-FoncillasPublished in: JCO precision oncology (2023)
Matching-adjusted indirect comparison analyses suggest longer OS with larotrectinib, compared with non-TRK-inhibitor SoC, in adult patients with TRK fusion-positive cancer.